Red cell distribution width is associated with long-term prognosis in patients with stable coronary artery disease

  • Tadeusz Osadnik1Email author,

    Affiliated with

    • Joanna Strzelczyk2,

      Affiliated with

      • Michał Hawranek1,

        Affiliated with

        • Andrzej Lekston1,

          Affiliated with

          • Jarosław Wasilewski1,

            Affiliated with

            • Anna Kurek1,

              Affiliated with

              • Aleksander Rafał Gutowski1,

                Affiliated with

                • Krzysztof Wilczek1,

                  Affiliated with

                  • Krzysztof Dyrbuś1,

                    Affiliated with

                    • Marek Gierlotka1,

                      Affiliated with

                      • Andrzej Wiczkowski2,

                        Affiliated with

                        • Mariusz Gąsior1,

                          Affiliated with

                          • Andrzej Szafranek1 and

                            Affiliated with

                            • Lech Poloński1

                              Affiliated with

                              BMC Cardiovascular Disorders201313:113

                              DOI: 10.1186/1471-2261-13-113

                              Received: 13 October 2013

                              Accepted: 1 December 2013

                              Published: 10 December 2013



                              Data regarding the association between red cell distribution width (RDW) values and mortality in patients with stable coronary artery disease are scarce. We aimed to investigate the link between mortality and RDW in patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI).


                              We analyzed 2550 consecutive patients with stable coronary artery disease who underwent PCI between 2007 and 2011 at our institution. The patients were divided into four groups according to RDW quartiles. The association between the RDW values and the outcomes was assessed using Cox proportional regression analysis after adjusting for clinical, echocardiographic, hemodynamic and laboratory data in the whole population and in subgroups stratified by gender, presence of diabetes, anemia or heart failure.


                              In the entire population, there was a stepwise relationship between RDW intervals and comorbidities. Patients with the highest RDW values were older and more often burdened with diabetes, heart failure and chronic kidney disease. There was an almost 4-fold increase in mortality during an average of 2.5 years of follow-up between the group of patients with RDW values lower than 13.1% (25th percentile) and the group with RDW values higher than 14.1% (75th percentile), (4.3% vs. 17.1%, p < 0.0001). After adjusting for the covariates, RDW remained significantly associated with mortality in the whole cohort (HR-1.23 [95% CI (1.13-1.35), p < 0.0001]) and in the subgroups stratified by gender, age (over and under 75 years), presence of anemia, diabetes, heart failure and chronic kidney disease.


                              Higher RDW values correspond to higher comorbidity burdens and higher mortality. RDW is an independent predictor of mortality in patients with stable coronary artery disease.


                              Red cell distribution width Stable coronary artery disease Prognosis


                              Red cell distribution width (RDW) is a numerical measure of erythrocyte variability and heterogeneity (i.e., anisocytosis). RDW is elevated in patients with anemia or thalassemia and after a blood transfusion or in the presence of iron deficiency [1]. The upper and lower limits of the RDW values were set at the 5th (11.0%) and 95th (14.0%) percentiles in a population from a National Health and Nutrition Examination Survey III study. In recent years there have been studies referring to patients with heart failure [2], with acute coronary syndromes [3] and unselected patients undergoing percutaneous coronary intervention (PCI) [4, 5] and various non-cardiological conditions [68]. To the best of our knowledge, there was only one smaller study referring to consecutive patients with stable coronary artery disease undergoing elective stent implantation with eight registered deaths in the 12 months follow-up [9], and two referring to subsets of patients with stable coronary artery disease [10, 11]. We aimed to investigate the link between mortality and RDW in the wide spectrum of patients with stable coronary artery disease undergoing PCI with stent implantation over long term follow-up.


                              Study group

                              Data from consecutive patients with stable coronary artery disease undergoing stent implantation between 2007 and 2011 at our institution (the Silesian Center for Heart Diseases) were analyzed. To identify patients with stable coronary artery disease, we screened all patients with the diagnosis codes of I25.0 and I25.2, as well as patients with other diagnoses who met the following criteria: i) elective hospital admission and ii) stent implantation. Patients undergoing concomitant transcatheter aortic valve implantation procedure, patients undergoing hybrid revascularization, and patients after orthotropic heart transplant were not considered in the first place. We have identified 2774 patients with stable coronary artery disease. Patients who died during hospitalization (n = 4), patients on dialysis (n = 11), those with advanced valve disease (n = 203), a history of cancer (n = 26) or other diseases potentially limiting survival (n = 18) were excluded from the analysis. Final cohort consisted of 2550 patients.

                              Data source

                              Starting in 2006, it has been compulsory for every attending physician at our Institution to fill out a complex report form for all admitted patients. This report form includes clinical data, past medical history and performed procedures. The form includes detailed data on a patient’s medical history and clinical characteristics at admission, and it resembles the cardiac report form used in clinical studies. Before patient documentation is given to the hospital information archive, the course of hospitalization is entered, and the report form is checked for completeness. Despite these strict measures, 11 (0.4%) patients were found to have missing data regarding information on the family history (FH) of premature coronary heart disease (CHD), Canadian Cardiovascular Society class, heart rate or systolic blood pressure (SBP) at admission. Data on ejection fraction were available for 2322 (91.1%) patients. Hemodynamic data were available for all patients and were taken from angiography descriptions. Creatinine, sodium levels and complete blood counts were available for all patients. The complete blood counts were performed using the Sysmex XS1000i and XE2100 (Sysmex Corporation, Kobe, Japan). Red cell distribution width (RDW) is calculated using the following formula: RDW = (standard deviation of red blood cell corpuscular volume)/(mean corpuscular volume (MCV)) × 100 [%]. The creation of the database of patients with stable coronary artery disease used in this study was supported by the National Science Center – Dec-2011/01/D/NZ5/04387. Study was approved by ethics committee at district chamber of physicians.

                              Statistical analysis

                              The continuous variables are presented as the means and standard deviations. The categorical variables are presented as percentages. Patients were divided into subgroups according to RDW quartiles. Group I (n = 607) comprised patients with an RDW < 13.1% (1st quartile), group II (n = 574) comprised patients with an RDW value of ≥13.1% and < 13.6% (2nd quartile), group III (n = 663) comprised patients with RDW values of ≥ 13.6% and <14.1% (3rd quartile) and group IV (n = 706) comprised patients with RDW values ≥ 14.1% (4th quartile). To test for differences across all groups, the chi square and Kruskall-Wallis tests were used.

                              Survival and regression analysis

                              The associations between the RDW quartiles and mortality were analyzed using the Kaplan-Meier method with log-rank testing. To assess the impact of the RDW on prognosis, a multivariate Cox regression analysis was performed. RDW was imputed as a continuous variable. To minimize the impact of missing data on the Cox regression analysis, the multiple imputation method was used to impute missing data for the variables that were to be included in the Cox regression procedures. The model was adjusted for age, sex, heart failure, atrial fibrillation, hypertension, previous myocardial infarction (MI), previous PCI, previous coronary artery bypass graft surgery (CABG), previous sudden cardiac death (SCD), peripheral vascular disease (PVD), previous stroke, diabetes, lipid abnormalities, obesity, chronic obstructive pulmonary disease (COPD), chronic kidney disease (CKD), smoking, New York Heart Association (NYHA) and CCS class, heart rate, blood pressure, ejection fraction, number and type(s) of stent implanted, number of PCI vessels, hemoglobin, MCV. Additionally stratified analyses according to gender, age (over or under 75 years) diabetes, CKD, anemia, and heart failure status were performed. Difference in Cox-model including aforementioned variables was compared with Cox model including additionally RDW using likelihood ratio test. Discriminative ability of those two models was assessed using Harrell’s C-statistics [12]. We have also compared those models by means of Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI). NRI estimates if the addition of new variable correctly increases or decreases the predicted risk for events and non-events [1316]. We have calculated NRI using predicted probabilities estimated by Cox regression analysis at the end of follow-up time. IDI describes differences in integrated sensitivity and integrated one minus specificity between models [13].

                              Follow-up data

                              Information on survival was based on the National Health Fund (NFZ) insurance status, which can be electronically verified. Because the NFZ insurance policy is obligatory for all Polish citizens, patients who were insured were marked as alive. We made an attempt to contact the relatives of uninsured patients and/or the relevant local registry office to obtain the exact date of death. Follow-up data were available for 2535 (99.4%) of patients. The mean follow-up period was 915.4 ± 525.3 days. During the observation period, there were 233 reported deaths. All reported p-values are two-sided. The analyses were performed using Number Crunching Statistical Systems 8.0 (NCSS, Kaysville, UT, USA) and in R software [17].


                              Baseline characteristics of the entire population

                              The baseline clinical characteristics for the entire population are shown in Table 1. In general, patients with the highest RDW values were older and more often burdened with diabetes, heart failure, CKD, COPD and PVD. Moreover, patients with higher RDW values had higher heart rates and lower ejection fractions. Not surprisingly, the lowest hemoglobin values were observed in patients with the highest RDW values (Table 2). The prescribed treatments at discharge reflected differences in comorbidities: more nitrates and diuretics were prescribed in patients with the highest RDW values (Table 3).
                              Table 1

                              Baseline clinical characteristics by quartiles of RDW


                              Group I

                              Group II

                              Group III

                              Group IV

                              P value

                              N = 607

                              N = 574

                              N = 663

                              N = 706


                              13.1 ≥ and <13.6%

                              13.6% ≥ and <14.1%


                              Age (yrs)

                              62.3 ± 9.5

                              63.3 ± 9.4

                              64.4 ± 9.3

                              65.6 ± 9.1


                              Men (%)

                              436 (71.8)

                              408 (71.1)

                              461 (69.5)

                              494 (70.0)


                              Heart failure

                              67 (11.0)

                              69 (12.0)

                              77 (11.7)

                              146 (20.7)


                              Atrial fibrillation

                              39 (6.4%)

                              50 (8.7%)

                              75 (11.3%)

                              123 (17.4)



                              428 (70.5)

                              431 (75.1)

                              477 (71.9)

                              491 (69.5)


                              Previous MI

                              343 (56.5%)

                              320 (55.7%)

                              373 (56.3%)

                              437 (61.9%)


                              Previous CABG

                              69 (11.4)

                              83 (14.5)

                              89 (13.4)

                              99 (14.0)


                              Previous PCI

                              307 (50.6)

                              274 (47.7)

                              306 (46.2)

                              367 (52.0)


                              Previous SCD

                              10 (1.6%)

                              20 (3.5)

                              21 (3.2)

                              26 (3.7)



                              24 (4.0)

                              34 (5.9)

                              37 (5.6)

                              47 (6.7)


                              Prev. Stroke/TIA

                              19 (3.1)

                              27 (4.7)

                              39 (5.9)

                              60 (8.5)


                              CKD GFR < 60 ml/h/1.73 m2

                              40 (6.6)

                              59 (10.3)

                              91 (13.7)

                              137 (19.4)



                              210 (34.6)

                              215 (37.5)

                              238 (35.9)

                              280 (39.7)



                              61 (10.0)

                              86 (15.0)

                              85 (12.8)

                              127 (18.0)


                              Lipid abnormalities

                              363 (59.8)

                              357 (62.2)

                              387 (58.4)

                              353 (50.0)



                              203 (33.4)

                              192 (33.4)

                              234 (35.3)

                              252 (35.7)



                              32 (5.3)

                              35 (6.1)

                              45 (6.8)

                              79 (11.2)


                              Current smoker

                              59 (9.7)

                              65 (11.3)

                              73 (11.0)

                              85 (12.0)


                              Previous smoker

                              202 (33.3%)

                              196 (34.1)

                              226 (34.1)

                              259 (36.7)


                              FH of premature CHD

                              65 (10.7)

                              48 (8.4)

                              70 (10.6)

                              47 (6.7)


                              NYHA class III/IV

                              28 (4.6%)

                              40 (7.0%)

                              33 (5.0%)

                              86 (12.2%)


                              Disabling angina (CCS III/IV)

                              97 (16.0)

                              92 (16.0)

                              115 (17.3)

                              115 (16.3)


                              HR (1/min)

                              69.3 ± 10.9

                              70.2 ± 11.4

                              71.9 ± 11.8

                              73.0 ± 12.9


                              SBP (mmHg)

                              133± 19.7

                              133.0 ± 19.7

                              132.3 ± 18.5

                              132 ± 20.6


                              DBP (mmHg)

                              79.3 ± 10.8

                              78.9 ± 11.3

                              78.8 ± 10.6

                              78.4 ± 12.0


                              Sinus rhythm -

                              588 (96.9)

                              547 (95.3)

                              620 (93.5)

                              632 (89.5)


                              Ejection fraction (%)

                              46.7 ± 9.7

                              47.8 ± 9.48

                              46.4 ± 10.0

                              43.8 ± 11.4



                              253 (41.7%)

                              284 (49.5%)

                              387 (58.4%)

                              435 (61.6%)



                              68 (11.2)

                              92 (16.0)

                              106 (16.0)

                              113 (16.0)


                              No. of PCI vessels

                              1.2 ± 0.5

                              1.2 ± 0.5

                              1.2 ± 0.5

                              1.3 ± 05


                              No. of stents

                              1.4 ± 0.7

                              1.4 ± 0.7

                              1.3 ± 0.6

                              1.4 ± 0.7


                              MI – myocardial infarction, CABG – coronary artery bypass graft, PCI – percutaneous coronary intervention, SCD – sudden cardiac death, PVD – peripheral vascular disease, FH – family history, CKD – chronic kidney disease, CHD – coronary heart disease, NYHA – New York Heart Association class, CCS – Canadian Cardiovascular Society class, HR – heart rate, SBP – systolic blood pressure, DBP – diastolic blood pressure, BMS – bare metal stent, MVD – multivessel disease.

                              Table 2

                              Laboratory findings by quartiles of RDW


                              Group I

                              Group II

                              Group III

                              Group IV

                              P value

                              N = 607

                              N = 574

                              N = 663

                              N = 706



                              13.1 ≥ and <13.6%

                              13.6% ≥ and <14.1%

                              ≥14.1 %


                              RBC (mln/mm3)

                              4.5 ± 0.4

                              4.5 ± 0.5

                              4.5 ± 0.5

                              4.5 ± 0.5


                              HGB (mmol/l)

                              8.7 ± 0.8

                              8.6 ± 0.9

                              8.6 ± 0.8

                              8.3 ± 1.0


                              HCT (%)

                              40.4 ± 3.4

                              40.6 ± 4.3

                              40.8 ± 3.8

                              39.8 ± 4.4


                              MCV (mm3)

                              90.6 ± 3.9

                              89.0 ± 3.8

                              90.5 ± 4.3

                              89.9 ± 5.6


                              RDW (%)

                              12.6 ± 0.4

                              13.3 ± 0.1

                              13.8 ± 0.2

                              15.0 ± 1.2


                              WBC (tys/mm3)

                              7.1 ± 1.9

                              7.3 ± 2.0

                              7.4 ± 2.6

                              7.4 ± 2.2


                              PLT (tys/mm3)

                              211.3 ± 51.3

                              210.0 ± 59.4

                              207.4 ± 60.6

                              213.3 ± 73.7


                              Creatinine (μmol/l)

                              79.8 ± 32.6

                              80,3 ± 22.8

                              83,2 ± 24.7

                              89,8 ± 48.1


                              GFR (ml/min/1.73 m2)

                              90.0 ± 21.9

                              89.4 ± 25.5

                              85.5 ± 24.2

                              82,4 ± 26.5


                              Sodium (mmol/l)

                              138.5 ± 2.6

                              138.3 ± 2.8

                              138.7 ± 2.64

                              138.5 ± 2.8


                              Glucose (mmol/l)

                              6.2 ± 2.0

                              6.1 ± 2.0

                              6.0 ± 1.6

                              5.9 ± 1.7


                              Cholesterol (mmol/l)

                              4.3 ± 1.1

                              4.5 ± 1.2

                              4.4 ± 1.1

                              4.5 ± 1.3


                              RBC – red blood cells, HGB – hemoglobin, HCT – hematocrit, MCV – mean corpuscular volume, RDW – red cell distribution width, WBC – white blood cells, PLT – platelets, GFR – glomerular filtration rate.

                              Table 3

                              Prescribed treatment at discharge by quartiles of RDW


                              Group I

                              Group II

                              Group III

                              Group IV

                              P value

                              N = 607

                              N = 574

                              N = 663

                              N = 706



                              13.1 ≥ and <13.6%

                              13.6% ≥ and <14.1%




                              601 (99.0)

                              569 (99.1)

                              658 (99.2)

                              693 (98.2)



                              607 (100)

                              572 (99.7)

                              658 (99.2)

                              699 (99.0)



                              585 (96.4)

                              539 (93.9)

                              622 (93.8)

                              641 (90.8)



                              581 (95.7)

                              555 (96.7)

                              630 (95.0)

                              671 (95.0)


                              Calcium channel blockers

                              106 (17.5)

                              82 (14.3)

                              100 (15.1)

                              112 (15.9)



                              203 (33.4)

                              194 (33.8)

                              229 (34.5)

                              315 (44.6)



                              121 (19.9)

                              166 (28.9)

                              223 (33.6)

                              233 (33.0)



                              23 (3.8)

                              32 (5.6)

                              47 (7.1)

                              83 (11.8)


                              ACE-I – angiotensin converting enzyme inhibitors, ARB – angiotensin receptor blockers, VKA – vitamin K antagonists.

                              Survival analysis and predictors of outcome

                              During the observation period, there were 233 reported deaths. Mortality in quartiles 1 to 3 was significantly lower as compared with quartile 4 (quartile 1 – 26 (4.3%); quartile 2 – 39 (6.8%); quartile 3–48 (7.3%); quartile 4–120 (17.1%), p < 0.0001, respectively) Figure 1. RDW was highly significantly associated with mortality in the entire cohort and in a subset of patients stratified by age, gender, anemia status, CKD, diabetes and heart failure (Table 4). Adding RDW to model based on clinical variables, ejection fraction hemodynamic data creatinine, and MCV resulted significantly improved the model (p < 0.001) although Harrell’s-C statistic increased only slightly from 0.76 (95% CI, 0.69÷0.82) to 0.77 (95% CI, 0.70÷0.83). Adding RDW to model based on clinical, hemodynamic and laboratory parameters (including MCV) however did not change IDI significantly (IDI - 0.019 95% CI: - 0.005 ÷ 0.051, p =0.120). There was also non-significant change in the risk of death predicted by the models with and without RDW (NRI - 0.251 95% CI: - 0.163 ÷ 0.512 p = 0.213).
                              Figure 1

                              Kaplan Meier survival curves by quartiles of RDW.

                              Table 4

                              Adjusted* hazard ratios of RDW [per 1% increase] in whole population and in subgroups


                              Hazard ratio

                              95% CI

                              P value

                              Whole group












                              ≥75 years




                              <75 years








                              Without anemia




                              With CKD




                              Without CKD








                              Without diabetes




                              Heart failure




                              Without heart failure




                              Adjusted for age, sex, heart failure, atrial fibrillation, hypertension, previous MI, previous PCI, previous CABG, previous SCD, PVD, previous stroke, diabetes, lipid abnormalities, obesity, COPD, CKDsmoking, NYHA and CCS class, heart rate, blood pressure, ejection fraction, number and type(s) of stent implanted, number of PCI vessels, hemoglobin, MCV.


                              There are two main findings of this study. First, with increasing values of RDW, there is an increase in the rate of patients with serious comorbidities such as COPD, PVD, diabetes treated with insulin, atrial fibrillation and heart failure in the entire population. Second, the RDW was associated with mortality, even after adjusting for clinical echocardiographic and hemodynamic variables in the whole population and in various subgroups. Mortality in the patients with the highest RDW values was almost 4-fold higher than in patients with the lowest RDW values. Similar results were obtained by Fatemi O. and Tonelli M. et al., who observed a graded relationship between RDW quartiles and mortality in patients with various forms of coronary artery disease [4, 11], and by Patel V.K., who reported an increase in mortality across RDW quintiles in the general population [18]. In a recent study, Ren H. et al. reported that similar trends of mortality and RDW may be present in patients with stable coronary artery disease because they registered 8 deaths (2.27%) vs. 2 deaths (0.51%) [9] in patients with RDW values in the highest and lowest RDW quartiles, respectively. Our analysis of a larger population with a longer follow-up period and 233 registered events confirms those findings.

                              RDW as a marker of disease burden

                              An increased percentage of patients with serious comorbidities compared to patients with lower RDW values suggests that RDW is a universal marker of disease burden. Data from analyses referring to the wide spectrum of diseases seem to confirm that finding [3, 1828]. Associations between higher RDW levels and CKD are quite easy to explain because anemia, which is frequently found in patients with impaired renal function [29, 30], is associated with increased RDW values. Moreover, RDW values are often used for anemia classification [31]. An explanation similar to that for CKD may hold for heart failure because Jankowska E et al. showed that iron deficiency develops during the progression of heart failure [32]. In our study, the frequency of heart failure and the percentage of patients with advanced heart failure symptoms were higher in patients with RDW values within the 4th quartile. The association of RDW with other comorbidities such as COPD, diabetes and peripheral vascular disease may be more difficult to elucidate. Possible explanations come from publications describing the increased inflammatory status and increased oxidative stress in those conditions [3338]. Therefore, in more advanced stages of atherosclerosis, COPD and diabetes, the detrimental effects of oxidative stress on erythrocyte membrane fluidity affects the lifespan of red blood cells, which in turn leads to higher RDW values [39]. However, Fornal M et al. and Lippi G et al. [40, 41] reported the existence of a potential link between inflammatory biomarkers and RDW values that may also be of importance, because the inflammation may impair iron metabolism and inhibit both the production of and the response to erythropoietin [18, 42]. Veranna V. et al. reported that RDW values of 12.6% and increased CRP levels above 3 mg/dl are associated with a higher risk of mortality in a cohort free of coronary heart disease [43]. Another interesting observation is the lower frequency of multivessel coronary artery disease (MVD) in patients with RDW values in the 1st quartile compared to the other quartiles, which is in concordance with results of Isik T. et al. and MA F-L [44, 45]. Those findings may indirectly confirm the association of increasing values of RDW with extensiveness and possibly the duration of the atherosclerotic process and the role of RDW as a marker of the disease process.

                              Red blood cell heterogeneity as a potential causative factor

                              The association between RDW values and comorbidities does not entirely explain the increased mortality in patients with the highest RDW values because RDW remained highly significantly associated with mortality after adjusting for clinical echocardiographic, hemodynamic and laboratory parameters in the entire cohort and in subgroups, although in our study it did not improve risk prediction as estimated by NRI and IDI measures. There have been however studies showing that RDW improves prediction of bleeding after acute coronary syndromes [46] and mortality in kidney transplant recipients [47].

                              Currently, it is not clear why higher RDW levels are so strongly associated with worse long term prognoses in various diseases. Luneva O.G. et al. provided insight into the pathophysiology of the relationship between mortality and RDW values by finding a significant correlation between RDW values and the cholesterol content of erythrocyte membranes, which also determines erythrocyte membrane fluidity [39]. It has also been reported that greater variation in RDW is associated with impaired blood flow through the microvascular system, which may cause tissue hypoxia, even in patients without anemia [48].

                              Strengths and limitations

                              A limitation of this study is the retrospective design. Nonetheless, the potential disadvantages of this retrospective analysis are diminished by the fact that the patient data are inputted into an electronic database from report forms filled out by the attending physician upon the patient’s admission to our center. Other limitations include a lack of iron status and other biomarkers such as high sensitivity troponins.

                              Strengths of this study include large cohort, detailed data on clinical, echocardiographic hemodynamic and laboratory parameters, and long follow-up period with very little patients lost to follow-up.


                              RDW is an independent predictor of mortality in patients with stable coronary artery disease undergoing stent implantation. Higher RDW values correspond with a higher comorbidity burden and higher mortality in a stepwise fashion, even within the RDW reference range.



                              Body mass index


                              Bare metal stent


                              Coronary artery bypass graft


                              Canadian Cardiovascular Society


                              Coronary heart disease


                              Chronic kidney disease


                              Chronic obstructive pulmonary disease


                              Diastolic blood pressure


                              Family history CHD


                              Glomerular filtration rate






                              Heart rate


                              Mean corpuscular volume


                              Myocardial infarction


                              Multivessel disease


                              New York Heart Association


                              Percutaneous coronary intervention


                              Platelet distribution width


                              Peripheral vascular disease


                              Red blood cells


                              Red cell distribution width


                              Systolic blood pressure


                              Sudden cardiac death


                              Transient ischemic attack


                              White blood cells.



                              We would like to thank Rafał Reguła, Roch Pakuła, Kamil Bujak, Małgorzata Gonera, Marcin Gawlita, Paweł Przybyło and Seweryn Król for imputing coronary angiography data into electronic database. We would like to thank attending physicians for fulfilling report forms for all admitted patients.

                              We would like to thank Assist. Prof. Kryspin Mirota for review of the manuscript for its statistical content.

                              Funding source

                              National Science Center – Dec-2011/01/D/NZ5/04387.

                              Authors’ Affiliations

                              IIIrd Chair and Department of Cardiology, Silesian Centre for Heart Diseases, Medical University of Silesia in Katowice, Medical Faculty in Zabrze
                              Department of Medical Biology, Medical University of Silesia in Katowice, Medical Faculty in Zabrze


                              1. Aung N, Ling HZ, Cheng AS, et al.: Expansion of the red cell distribution width and evolving iron deficiency as predictors of poor outcome in chronic heart failure. Int J Cardiol 2013,168(3):1997–2002. doi: 10.1016/j.ijcard.2012.12.091PubMedView Article
                              2. Emans ME, Gaillard CAJM, Pfister R, et al.: Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC—Norfolk study. Int J Cardiol 2013,168(4):3550–3355. doi: 10.1016/j.ijcard.2013.05.002. Epub 2013 May 24PubMedView Article
                              3. Nabais S, Losa N, Gaspar A, et al.: Association between red blood cell distribution width and outcomes at six months in patients with acute coronary syndromes. Rev Port Cardiol 2009,28(9):905–924.PubMed
                              4. Fatemi O, Paranilam J, Rainow A, et al.: Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention. J Thromb Thrombolysis 2013,35(1):57–64.PubMedView Article
                              5. Arbel Y, Birati EY, Finkelstein A, et al.: Red blood cell distribution width and 3-year outcome in patients undergoing cardiac catheterization. J Thromb Thrombolysis 2013. [Epub ahead of print] ACCESSED ON 04.12.2013
                              6. Celikbilek A, Zararsiz G, Atalay T, Tanik N: Red cell distribution width in migraine. Int J Lab Hematol 2013,35(6):620–628. doi: 10.1111/ijlh.12100. Epub 2013 May 7PubMed
                              7. Afonso L, Zalawadiya SK, Veeranna V, Panaich SS, Niraj A, Jacob S: Relationship between red cell distribution width and microalbuminuria: a population-based study of multiethnic representative US adults. Nephron Clin Pract 2011,119(4):c277-c282.PubMedView Article
                              8. Fujita B, Strodthoff D, Fritzenwanger M, et al.: Altered red blood cell distribution width in overweight adolescents and its association with markers of inflammation. Pediatr Obes 2012,8(5):385–391. doi: 10.1111/j.2047–6310.2012.00111.x. Epub 2012 Dec 13PubMedView Article
                              9. Ren H, Hua Q, Quan M, et al.: Relationship between the red cell distribution width and the one-year outcomes in Chinese patients with stable Angina Pectoris. Intern Med 2013,52(16):1769–1774.PubMedView Article
                              10. Tsuboi S, Miyauchi K, Kasai T, et al.: Impact of red blood cell distribution width on long-term mortality in diabetic patients after percutaneous coronary intervention. Circ J 2013,77(2):456–461.PubMedView Article
                              11. Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M: Relation between red blood cell distribution width and cardiovascular event rate in people with coronary disease. Circulation 2008,117(2):163–168.PubMedView Article
                              12. Harrell Jr FE, with contributions from Charles Dupont and many others: Hmisc: Harrell Miscellaneous. R package version 3.13–0. http://​CRAN.​R-project.​org/​package=​Hmisc R package version 3.13-0.
                              13. Pencina MJ, D’Agostino RB, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011,30(1):11–21.PubMed CentralPubMedView Article
                              14. Pencina MJ, D’Agostino RB, Vasan RS: Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008,27(2):157–172. discussion 207–12PubMedView Article
                              15. Beleigoli AM, Boersma E, de FH DM, Vidigal PG, Lima-Costa MF, Ribeiro AL: C-reactive protein and B-type natriuretic Peptide yield either a non-significant or a modest incremental value to traditional risk factors in predicting long-term overall mortality in older adults. PLoS One 2013,8(9):e75809.PubMed CentralPubMedView Article
                              16. Hajime Uno and Tianxi Cai: survIDINRI: I and N, Survival comparing competing risk prediction models with censored, 1.1–1. data. 2013. R package version 1.1–1. http://​CRAN.​R-project.​org/​package=​survIDINRI
                              17. Statistical RCT: RA language and environment for, computing. Vienna A: R Foundation for Statistical Computing; 2013. Http://​www.​R-project.​org/​
                              18. Patel KV, Ferrucci L, Ershler WB, Longo DL, Guralnik JM: Red blood cell distribution width and the risk of death in middle-aged and older adults. Arch Intern Med 2009,169(5):515–523.PubMed CentralPubMedView Article
                              19. Yu S, Cui H, Qin M, et al.: Impact of red cell distribution width on outcome of 16 681 patients with chronic systolic heart failure. Zhonghua Xin Xue Guan Bing Za Zhi 2012,40(3):237–242.PubMed
                              20. Ujszaszi A, Molnar MZ, Czira ME, Novak M, Mucsi I: Renal function is independently associated with red cell distribution width in kidney transplant recipients: a potential new auxiliary parameter for the clinical evaluation of patients with chronic kidney disease. Br J Haematol 2013,161(5):715–725.PubMedView Article
                              21. Ozsu S, Abul Y, Gunaydin S, Orem A, Ozlu T: Prognostic value of red cell distribution width in patients with pulmonary embolism. Clin Appl Thromb Hemost 2012. [Epub ahead of print] ACCESSED ON 04.12.2013
                              22. Seyhan EC, Ozgül MA, Tutar N, Omür I, Uysal A, Altın S: Red blood cell distribution and survival in patients with chronic obstructive pulmonary disease. COPD 2013,10(4):416–424. doi: 10.3109/15412555.2012.758697. Epub 2013 Mar 28PubMedView Article
                              23. Balta S, Demirkol S, Cakar M, Ardic S, Celik T, Demirbas S: Red cell distribution width: a novel and simple predictor of mortality in acute pancreatitis. Am J Emerg Med 2013,31(6):991–992. doi: 10.1016/j.ajem.2013.02.037. Epub 2013 Apr 17PubMedView Article
                              24. Ford HC, Toomath RJ, Carter JM, Delahunt JW, Fagerstrom JN: Mean platelet volume is increased in hyperthyroidism. Am J Hematol 1988,27(3):190–193.PubMedView Article
                              25. Zalawadiya SK, Veeranna V, Panaich SS, Afonso L: Red cell distribution width and risk of peripheral artery disease: analysis of National Health and Nutrition Examination Survey 1999–2004. Vasc Med 2012,17(3):155–163.PubMedView Article
                              26. Sincer I, Zorlu A, Yilmaz MB, et al.: Relationship between red cell distribution width and right ventricular dysfunction in patients with chronic obstructive pulmonary disease. Heart Lung 2012,41(3):238–243.PubMedView Article
                              27. Montagnana M, Cervellin G, Meschi T, Lippi G: The role of red blood cell distribution width in cardiovascular and thrombotic disorders. Clin Chem Lab Med 2012,50(4):635–641.
                              28. Jo YH, Kim K, Lee JH, et al.: Red cell distribution width is a prognostic factor in severe sepsis and septic shock. Am J Emerg Med 2013,31(3):545–548.PubMedView Article
                              29. Hsu CY, Bates DW, Kuperman GJ, Curhan GC: Relationship between hematocrit and renal function in men and women. Kidney Int 2001,59(2):725–731.PubMedView Article
                              30. Kitai Y, Ozasa N, Morimoto T, et al.: Prognostic implications of anemia with or without chronic kidney disease in patients undergoing elective percutaneous coronary intervention. Int J Cardiol 2013,168(6):5221–5228. doi: 10.1016/j.ijcard.2013.08.029. Epub 2013 Aug 16PubMedView Article
                              31. Karnad A, Poskitt TR: The automated complete blood cell count. Use of the red blood cell volume distribution width and mean platelet volume in evaluating anemia and thrombocytopenia. Arch Intern Med 1985,145(7):1270–1272.PubMedView Article
                              32. Jankowska EA, Malyszko J, Ardehali H, et al.: Iron status in patients with chronic heart failure. Eur Heart J 2013,34(11):827–834.PubMedView Article
                              33. Vanfleteren LEGW, Spruit MA, Groenen M, et al.: Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013,187(7):728–735.PubMedView Article
                              34. Van den Borst B, Gosker HR, Koster A, et al.: The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. Am J Clin Nutr 2012,96(3):516–526.PubMed CentralPubMedView Article
                              35. Kirkham PA, Barnes PJ: Oxidative stress in COPD. Chest 2013,144(1):266–273.PubMedView Article
                              36. Vaziri ND: Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clin Exp Nephrol 2013. [Epub ahead of print]
                              37. Gardner AW, Parker DE, Montgomery PS, et al.: Impaired vascular endothelial growth factor A and inflammation in patients with peripheral artery disease. Angiology 2013. [Epub ahead of print] ACCESSED ON 04.12.2013
                              38. Cai L, Kang YJ: Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001,1(3):181–193.PubMedView Article
                              39. Luneva OG, Brazhe NA, Maksimova NV, et al.: Ion transport, membrane fluidity and haemoglobin conformation in erythrocyte from patients with cardiovascular diseases: role of augmented plasma cholesterol. Pathophysiology 2007,14(1):41–46.PubMedView Article
                              40. Fornal M, Wizner B, Cwynar M, et al.: Association of red blood cell distribution width, inflammation markers and morphological as well as rheological erythrocyte parameters with target organ damage in hypertension. Clin Hemorheol Microcirc 2013. doi: 10.3233/CH-131745
                              41. Lippi G, Targher G, Montagnana M, Salvagno GL, Zoppini G, Guidi GC: Relationship between red blood cell distribution width and kidney function tests in a large cohort of unselected outpatients. Scand J Clin Lab Invest 2008,68(8):745–748.PubMedView Article
                              42. Weiss G, Goodnough LT: Anemia of chronic disease. N Engl J Med 2005,352(10):1011–1023.PubMedView Article
                              43. Veeranna V, Zalawadiya SK, Panaich S, Patel KV, Afonso L: Comparative analysis of red cell distribution width and high sensitivity C-reactive protein for coronary heart disease mortality prediction in multi-ethnic population: Findings from the 1999–2004 NHANES. Int J Cardiol 2013,168(6):5156–5161. doi: 10.1016/j.ijcard.2013.07.109. Epub 2013 Sep 7PubMedView Article
                              44. Isik T, Kurt M, Ayhan E, et al.: Relation of red cell distribution width with presence and severity of coronary artery ectasia. Clin Appl Thromb Hemost 2012,18(5):441–447.PubMedView Article
                              45. Ma F-L, Li S, Li X-L, et al.: Correlation of red cell distribution width with the severity of coronary artery disease: a large Chinese cohort study from a single center. Chin Med J (Engl) 2013,126(6):1053–1057.
                              46. Fatemi O, Torguson R, Chen F, et al.: Red cell distribution width as a bleeding predictor after percutaneous coronary intervention. Am Heart J 2013,166(1):104–109.PubMedView Article
                              47. Mucsi I, Ujszaszi A, Czira ME, Novak M, Molnar MZ: Red cell distribution width is associated with mortality in kidney transplant recipients. Int Urol Nephrol 2013. [Epub ahead of print] PMID:23959402
                              48. Patel KV, Mohanty JG, Kanapuru B, Hesdorffer C, Ershler WB, Rifkind JM: Association of the red cell distribution width with red blood cell deformability. Adv Exp Med Biol 2013, 765:211–216.PubMedView Article
                              49. Pre-publication history

                                1. The pre-publication history for this paper can be accessed here:http://​www.​biomedcentral.​com/​1471-2261/​13/​113/​prepub


                              © Osadnik et al.; licensee BioMed Central Ltd. 2013

                              This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.